Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron/Ortho Diagnostic Systems

This article was originally published in The Gray Sheet

Executive Summary

Receive FDA product license on June 22 for the Chiron RIBA HCV 2.0 strip immunoblot assay, a supplemental test for the detection of hepatitis C virus. The firms say the assay is intended for use as "an additional, more specific test for specimens found to be reactive in HCV antibody screening procedures." They add that the product is a three-stage test utilizing recombinant HCV antigens that "helps physicians to more accurately diagnose past or present hepatitis C infections" by providing "additional information." The HCV 2.0 is the third HCV testing system to result from the companies' collaboration ("The Gray Sheet" March 16, p. 3). Sales will begin the week of June 28.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel